

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. to 6. (Canceled).

7. (Currently Amended) A method of evaluating the effectiveness of an HIV-1 antiviral therapy of an ~~HIV~~-HIV-1 infected patient comprising:

- (i) collecting a sample from an ~~HIV~~-HIV-1 infected patient;
- (ii) ~~Determining~~detecting in said sample each of the following nucleic acids:
 - a) a first nucleic acid encoding an ~~HIV~~HIV-1 reverse transcriptase

comprising:

- 1) at least one mutation chosen from the group consisting of 88E, 101H, 101N, 101P, 101Q, 101T, 103H, 103S, 179I, 179E, 181V, 190E, 190S and 190T; or

- 2) a combination of -mutations 103R and 179D,

in which the presence of said first nucleic acid correlates with resistance to -a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI);

- b) a second nucleic acid encoding an ~~HIV~~-HIV-1 reverse transcriptase comprising at least one mutation chosen from the group consisting of ~~69S-[S-S], 69S-[S-S]~~, 184G, 215V, 44D, 44A, and 118I,

in which the presence of said second nucleic acid correlates with resistance to -a Nucleoside Reverse Transcriptase Inhibitor (NRTI); and

- c) a third nucleic acid encoding an ~~HIV~~-HIV-1 protease comprising:

- 1) mutation 88T; or

- 2) a combination of -mutations 33F and 90M,

in which the presence of said third nucleic acid correlates with resistance to -a Protease Inhibitor (PI);

whereby the presence of ~~each one~~ of the nucleic acids in step (ii) individually correlates with the effectiveness ~~of said~~ HIV-1 antiviral therapy.

Application No.: 09/580,491

Docket No.: **VIP 0004US**
EFS Amendment: July 21, 2008

8. to 37. (Canceled).